Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 11/20 | 0.51 |
| ▸ | HTR1B | P28222 | 10/20 | 0.51 |
| ▸ | HTR1F | P30939 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8383732 | 0.97 | HTR1D (0.49) | HTR1DHTR1BNOS3NOS1 | |
| Glycolic Acid SCHEMBL30908835 | 0.93 | HTR1D (0.45) | HTR1DHTR1BNOS3NOS1 | |
| Cadaverine Tartrate SCHEMBL8383868 | 0.85 | HTR1D (0.42) | HTR1DHTR1BNOS3NOS1 | |
| SCHEMBL8382055 | 0.84 | NOS3 (0.42) | HTR1DHTR1BHTR1FNOS3NOS1 | |
| SCHEMBL8387008 | 0.82 | NOS3 (0.40) | HTR1DHTR1BNOS3NOS1 | |
| SCHEMBL8385366 | 0.82 | NOS3 (0.41) | HTR1DHTR1BNOS3NOS1 | |
| SCHEMBL8385339 | 0.82 | NOS3 (0.44) | HTR1DHTR1BHTR1FNOS3NOS1 | |
| SCHEMBL8387132 | 0.82 | HTR1D (0.43) | HTR1D | |
| SCHEMBL8381630 | 0.81 | NOS1 (0.46) | HTR1DHTR1BNOS3NOS1SMN1; SMN2 | |
| SCHEMBL8387518 | 0.81 | MEN1 (0.44) | HTR1DHTR1BHTR1FNOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| US-5874427-A | MIGRAINE | ELI LILLY AND COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0875513-A1 | Substituted heteroaromatic 5-HT 1F agonists | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR1D 3/4885HTR1B 4/4885HTR1F 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.